Format
Sealed research vial
Trust signal
COA-backed inventory
Safety Data Sheet
Download SDS
Full safety documentation for this compound.
99%+ Purity
Lab-grade supply. Limited AU stock.
From A$64.99
Select options below
Size
Select one
Select your preferred options to continue.
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
Certificate of Analysis
Verified purity: Available in document
Tirzepatide is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 3 labelled variants: 10mg, 20mg, and 15mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.
Within the wider Au Peptide Labs catalogue, Tirzepatide sits alongside BPC-157, MOTS-c, and Semax. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.
Browse Inventory
In research literature, Tirzepatide is generally treated as a 39-amino acid dual GIP/GLP-1 receptor agonist with a C20 fatty diacid moiety linked via a γGlu-2×OEG spacer at Lys26. Tirzepatide engages both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1R, each coupling through Gs to stimulate cAMP production. Its GIPR agonism shows a differentiated β-arrestin recruitment profile relative to native GIP in cellular assays — sometimes described as partial or biased agonism — which creates distinct receptor internalisation kinetics compared with full-efficacy GIPR agonists. At GLP-1R it behaves as a full agonist with potency comparable to semaglutide in cAMP accumulation assays. The C20 fatty diacid modification confers tight albumin binding, supporting comparative half-life studies against C18-modified analogs.
Dual-receptor research panels using tirzepatide typically aim to dissect how simultaneous GIP and GLP-1 pathway activation changes the net cAMP response, receptor trafficking, or downstream transcriptional outputs versus each pathway individually. Its biased GIPR profile makes it an informative tool for structure-activity studies in receptor pharmacology. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether Tirzepatide behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for Tirzepatide should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for Tirzepatide is:
A product-specific COA is linked on this page, with purity noted as available in the document. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare Tirzepatide with BPC-157, MOTS-c, and Semax, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
Certificate of Analysis
Verified purity: Available in document
It brings together 3 labelled variants: 10mg, 20mg, and 15mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
Tirzepatide is generally discussed as a 39-amino acid dual GIP/GLP-1 receptor agonist with a C20 fatty diacid moiety linked via a γGlu-2×OEG spacer at Lys26. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
Yes. This listing includes access to a product-specific COA, which should be reviewed before use so purity, identity, and documentation checks are aligned with the project record.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
